Media stories about Relypsa (NASDAQ:RLYP) have been trending somewhat positive on Friday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Relypsa earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.1581618172143 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Relypsa (NASDAQ RLYP) opened at $31.99 on Friday. Relypsa has a fifty-two week low of $10.26 and a fifty-two week high of $32.12.

ILLEGAL ACTIVITY NOTICE: “Relypsa (RLYP) Receiving Somewhat Favorable Media Coverage, Report Shows” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/10/relypsa-rlyp-receiving-somewhat-favorable-media-coverage-report-shows.html.

Relypsa Company Profile

Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.

Insider Buying and Selling by Quarter for Relypsa (NASDAQ:RLYP)

Receive News & Stock Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related stocks with our FREE daily email newsletter.